Animal Or Plant Cell Patents (Class 424/93.7)
-
Patent number: 11925383Abstract: A medical device is disclosed that can help prevent a guide wire from coming into contact with a rotating body in the middle of performing a treatment and achieves improvement in the efficiency of cutting an object by the rotating body. The medical device has a sheath that is insertable into a body lumen, a rotatable hollow rotating body that is disposed to protrude toward a distal side of the sheath, and guide wire lumens into which a guide wire w is insertable in parallel with the sheath. A distal surface of the rotating body has corrugated portions.Type: GrantFiled: November 27, 2019Date of Patent: March 12, 2024Assignee: TERUMO KABUSHIKI KAISHAInventors: Yuichi Tada, Mizuho Hirao
-
Patent number: 11920160Abstract: Production of beta-cells from stem cells from pluripotent stem cells have always been significantly lacking in at least one of the following properties: 1) functional properties related to insulin-production and glucose signaling response, 2) mature phenotype such as biochemical markers or cell structures, 3) efficiency in production of differentiated cells. Described herein is multistep differentiation protocol which substantially overcomes all of the existing limitations. Pluripotent stem cells, including induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs) can be differentiated using an embryoid body (EB) formation step, followed by B maturation via endothelial cells (EC) co-culturing and incubation with a sequential series of bone morphogenic protein (BMP)-related growth factor cocktails. The resulting cells displayed functional properties, including insulin-production and glucose signaling response, and mature phenotype of C-peptide expression.Type: GrantFiled: February 21, 2014Date of Patent: March 5, 2024Assignee: Cedars-Sinai Medical CenterInventors: Dodanim Talavera-Adame, Donald C. Dafoe
-
Patent number: 11891627Abstract: Provided is an apparatus and process for isolation of stromal vascular fraction (SVF) following lipoaspiration.Type: GrantFiled: June 9, 2016Date of Patent: February 6, 2024Assignee: THE MEDICAL RESEARCH, INFRASTRUCTURE, AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTERInventors: Nir Shani, Eyal Gur, Inna Solodeev, Anna Aronovich
-
Patent number: 11891622Abstract: A population of human polygonal RPE cells is disclosed. At least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms. Methods of generating same are also disclosed.Type: GrantFiled: December 30, 2015Date of Patent: February 6, 2024Assignee: CELL CURE NEUROSCIENCES LTD.Inventors: Osnat Bohana-Kashtan, Lior Ann Rosenberg Belmaker, Ofer Wiser
-
Patent number: 11873507Abstract: The present disclosure relates to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified alphavirus virus viral genome or self-replicating RNA (srRNA) construct, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting a pharmacodynamics effect in a subject.Type: GrantFiled: November 29, 2021Date of Patent: January 16, 2024Assignee: Replicate Bioscience, Inc.Inventors: Nathaniel Stephen Wang, Shigeki Joseph Miyake-Stoner, Parinaz Aliahmad
-
Patent number: 11872258Abstract: Embodiments of the invention include a system having a plant stem cell product and a delivery device configured to deliver an effective amount of the plant stem cell product to the oral cavity or nasopharynx. In some embodiments, the delivery device may include an aerosolizing device, an adherent dressing, a tooth-adherent flexible strip, a treatment tray, a viscous adherent carrier, a brush, a paste, a flosser, a dissolving oral strip, a gum, a chew, a smoking material, a nasal packing, or a lozenge. The plant stem cell products may include encapsulated extracts of plant stem cells, such as food species stem cells, spice or other seasoning stem cells, or medicinal plant stem cells.Type: GrantFiled: November 24, 2019Date of Patent: January 16, 2024Assignee: StemStix, Inc.Inventor: Maryam Rahimi
-
Patent number: 11865189Abstract: The present invention relates to methods and composition for use in the treatment of retinal degeneration, in particular retinal degeneration due to retinal pigment epithelium dysfunction.Type: GrantFiled: December 17, 2015Date of Patent: January 9, 2024Assignees: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Thierry Leveillard, Christo Kole, Jose-Alain Sahel
-
Patent number: 11857610Abstract: This disclosure relates to methods for preventing or reducing the risk of development of graft versus host disease (GVHD) in patients receiving hematopoietic cell transplantation (HCT) by particular methods of administering alpha-1 antitrypsin (A1AT or AAT) to patients both prior to and following and HCT procedure. The disclosure also relates to specific methods of treating acute GVHD (aGVHD) after HCT with A1AT.Type: GrantFiled: November 30, 2018Date of Patent: January 2, 2024Assignee: CSL Behring LLCInventors: Marc Uknis, Christine Voigt, Gautam Baheti, John Roberts
-
Patent number: 11840706Abstract: The present invention is concerned with a composition and in vitro method for generating a desired cell type and/or tissue type from hair follicular stem cells. The composition and in vitro method are particularly suitable for generating an autologous desired cell type and/or tissue type. Furthermore, the composition and method are especially efficient and suitable for use in the context of cosmetic cell and/or tissue transplantation in recipient areas of a subject experiencing cell and/or tissue loss caused by, for example, a wound, scar, burn injury, tissue degeneration, and aging. The composition and in vitro method are also suitable to circumvent complications related to infections and/or immune rejection of a cosmetic cell and/or tissue implant or graft.Type: GrantFiled: July 13, 2023Date of Patent: December 12, 2023Inventor: Conradus Ghosal Gho
-
Patent number: 11840732Abstract: A method for determining one or more tumour properties in a subject with a tumour, the method comprising:—seeding a cell-free scaffold obtained from the tumour with cancer cells;—culturing the cancer cells in the scaffold;—assaying the cultured cancer cells for the presence of target molecules indicative of the expression of one or more genes in the cells; and—determining one or more tumour properties based on the results of the assay.Type: GrantFiled: November 3, 2017Date of Patent: December 12, 2023Assignee: ISCAFF PHARMA ABInventors: Göran Landberg, Anders Ståhlberg, Joakim Håkansson
-
Patent number: 11833512Abstract: An in vitro microfluidic “organ-on-chip” is described herein that mimics the structure and at least one function of specific areas of the epithelial system in vivo. In particular, a multicellular, layered, microfluidic culture is described, allowing for interactions between lamina propria-derived cells and the associated tissue specific epithelial cells and endothelial cells. This in vitro microfluidic system can be used for modeling inflammatory tissue, e.g., autoimmune disorders involving epithelia and diseases involving epithelial layers. These multicellular, layered microfluidic “organ-on-chip”, e.g. “epithelia-on-chip” further allow for comparisons between types of epithelia tissues, e.g., lung (Lung-On-Chip), bronchial (Airway-On-Chip), skin (Skin-On-Chip), cervix (Cervix-On-Chip), blood brain barrier (BBB-On-Chip), etc., in additional to neurovascular tissue, (Brain-On-Chip), and between different disease states of tissue, i.e. healthy, pre-disease and diseased areas.Type: GrantFiled: March 29, 2021Date of Patent: December 5, 2023Assignee: EMULATE, INC.Inventors: S. Jordan Kerns, Riccardo Barrile, Geraldine Hamilton, Catherine Karalis, Daniel Levner, Carolina Lucchesi, Antonio Varone, Remi Villenave
-
Patent number: 11814757Abstract: A method of forming a substrate includes mapping a three dimensional spatial distribution of at least one structural protein fiber of extracellular matrix of biological material of interest, designing a fiber assembly pattern based on an intrinsic pattern of the at least one structural protein fiber of the extracellular matrix of the biological material, and assembling fibers based on the fiber assembly pattern to form the substrate.Type: GrantFiled: June 15, 2016Date of Patent: November 14, 2023Assignee: BIOCONIX PTY LTD.Inventor: Melissa Knothe Tate
-
Patent number: 11779609Abstract: A notochordal cell matrix solution as a bioactive lubricant in the treatment of Osteoarthritis, more specifically for use as a bioactive lubricant in viscosupplementation. The notochordal cell matrix solution is capable of reducing the pain in osteoarthritic joints.Type: GrantFiled: January 30, 2019Date of Patent: October 10, 2023Assignee: TECHNISCHE UNIVERSITEIT EINDHOVENInventors: Keita Ito, Stefan Antonius Henricus De Vries
-
Patent number: 11759549Abstract: An interpenetrating polymer network (IPN) structured hydrogel includes a crosslinked first natural polymer macromer with a first elasticity and an interpenetrating network of crosslinked second natural polymer macromers having a second elasticity higher than the first elasticity, the IPN structured hydrogel being cytocompatible, and, upon degradation, produce substantially non-toxic products.Type: GrantFiled: August 21, 2018Date of Patent: September 19, 2023Assignee: CASE WESTERN RESERVE UNIVERSITYInventor: Eben Alsberg
-
Patent number: 11760973Abstract: In an aspect, compositions, methods, and devices described herein provide a safer platform for the ex vivo expansion of cells for immunotherapeutic purposes that eradicates the possibility of having activating substrate transferred into the patient while maintaining and improving upon the level of cell activation and proliferation.Type: GrantFiled: May 3, 2017Date of Patent: September 19, 2023Assignee: The Trustees of Columbia University in the City of New YorkInventors: Alex Dang, Lance C. Kam
-
Patent number: 11738117Abstract: Compositions and methods of transplanting cells by grafting strategies into solid organs (especially internal organs) are provided. These methods and compositions can be used to repair diseased organs or to establish models of disease states in experimental hosts. The method involves attachment onto the surface of a tissue or organ, a patch graft, a “bandaid-like” covering, containing epithelial cells with supporting early lineage stage mesenchymal cells. The cells are incorporated into soft gel-forming biomaterials prepared under serum-free, defined conditions comprised of nutrients, lipids, vitamins, and regulatory signals that collectively support stemness of the donor cells. The graft is covered with a biodegradable, biocompatible, bioresorbable backing used to affix the graft to the target site. The cells in the graft migrate into and throughout the tissue such that within a couple of weeks they are uniformly dispersed within the recipient (host) tissue.Type: GrantFiled: June 12, 2018Date of Patent: August 29, 2023Assignee: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventors: Lola M. Reid, Wencheng Zhang, Eliane Wauthier
-
Patent number: 11730765Abstract: The present disclosure provides compositions and methods for targeted delivery of therapeutic agents. The present disclosure further provides methods for treating or preventing the metastasis or recurrence of a cancer using platelets loaded with a therapeutic agent (for example, an immunotherapeutic agent).Type: GrantFiled: September 13, 2017Date of Patent: August 22, 2023Assignee: North Carolina State UniversityInventors: Zhen Gu, Chao Wang
-
Patent number: 11723928Abstract: This document provides methods and materials for treating multiple system atrophy. For example, methods and materials for using autologous mesenchymal stem cells (e.g., adipose derived mesenchymal stem cells) to treat multiple system atrophy are provided.Type: GrantFiled: August 12, 2022Date of Patent: August 15, 2023Assignee: Mayo Foundation for Medical Education and ResearchInventors: Wolfgang Singer, Phillip Low
-
Patent number: 11707491Abstract: A method of treating a mammal with one of a central nervous system injury and a neurodegenerative disorder comprising isolating, culturing, and generating neural progenitor cells from a mammalian placenta, and transplanting the placenta derived neural progenitor cells into a brain of the mammal.Type: GrantFiled: November 13, 2017Date of Patent: July 25, 2023Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Yuping Wang, Xiaohong Lu
-
Patent number: 11697798Abstract: A method to increase the efficiency of myotube generation and maturation from pluripotent stem cells comprising: (a) differentiating pluripotent stem cells to myogenic progenitors; and (b) terminally differentiating said myogenic progenitors from (a) into myotubes in the presence of at least one gamma secretase inhibitor, wherein myotube generation is increased in the presence of at least one gamma secretase inhibitor, as compared to differentiation in the absence of gamma secretase inhibitors.Type: GrantFiled: December 13, 2018Date of Patent: July 11, 2023Assignee: Regents of the University of MinnesotaInventors: Rita Perlingeiro, Sridhar Selvaraj, Ricardo Mondragon Gonzalez
-
Patent number: 11679126Abstract: Methods of tissue grafting, and more particularly methods for enhancing tissue graft revascularization, e.g., host engagement of pre-existing graft blood vessels.Type: GrantFiled: November 17, 2017Date of Patent: June 20, 2023Assignee: Chldren's Medical Center CorporationInventors: Juan M. Melero-Martin, Ruei-Zeng Lin
-
Patent number: 11679128Abstract: Methods of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of peripheral blood mononuclear cells (PBMCs) from a sample of peripheral blood; (b) specifically selecting CD8+ T cells that also express PD-1 and/or TIM-3 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells are disclosed. Related methods of administering a cell population enriched for tumor-reactive T cells to a mammal, methods of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, and isolated or purified cell populations are also disclosed.Type: GrantFiled: June 5, 2020Date of Patent: June 20, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Alena Gros, Steven A. Rosenberg
-
Patent number: 11661586Abstract: Compositions comprising (i) lactate oxidase (LOX) and Catalase (CAT), preferably in a 1:1 molar ratio; or (ii) a fusion polypeptide comprising both LOX and CAT, e.g., LOXCAT, and methods of use thereof for reducing blood lactate levels, increasing blood pyruvate levels, and/or decreasing blood lactate/pyruvate ratio in a subject.Type: GrantFiled: December 3, 2018Date of Patent: May 30, 2023Assignee: The General Hospital CorporationInventors: Vamsi K. Mootha, Xiaoyan Robert Bao, Anupam Patgiri
-
Patent number: 11654181Abstract: This invention relates to C-X-C motif chemokine 12 (CXCL12), also known as stromal cell-derived factor 1 (SDF-1), vectors encoding the same, and methods of using the same for a male subject that has undergone prostate surgery to treat urological symptoms of the surgery.Type: GrantFiled: August 10, 2018Date of Patent: May 23, 2023Assignee: Wake Forest University Health SciencesInventor: James K. Williams
-
Patent number: 11646103Abstract: Contemplated systems and methods use high-accuracy in silico HLA analysis of omics data of donor tissue samples to so establish a transplant match database suitable for transplantation, and particularly stem cell and solid organ transplant, including identification of a donor tissue sample as being compatible with a recipient having a matching HLA type.Type: GrantFiled: September 5, 2018Date of Patent: May 9, 2023Assignee: Nant Holdings IP, LLCInventors: Patrick Soon-Shiong, John Zachary Sanborn
-
Patent number: 11633442Abstract: The present invention relates to augmenting the effects of adoptive T cell therapy, such as TVAX Immunotherapy, using adjunct treatment with an oncolytic virus, such as a vaccinia virus, to treat various types of cancer or other proliferative disorders. Immunomodulatory compounds can be used to further augment to effects of the therapy.Type: GrantFiled: July 27, 2020Date of Patent: April 25, 2023Assignee: TVAX BIOMEDICAL I, LLCInventors: Gary Wood, Jochen Harald Stritzker
-
Patent number: 11630103Abstract: The present invention provides isolated immune cells, immune cell populations and compositions, as well as markers, marker signatures and molecular targets characterising the immune cells. The cell products, substances, compositions, markers, marker signatures, molecular targets, kits of parts and methods of the present invention provide for new ways to characterise, evaluate and modulate the immune system and immune responses.Type: GrantFiled: August 17, 2017Date of Patent: April 18, 2023Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The General Hospital CorporationInventors: Alexandra-Chloé Villani, Rahul Satija, Aviv Regev, Nir Hacohen
-
Patent number: 11624053Abstract: The present invention provides a method of culturing corneal endothelial cells. More specifically, the present invention provides a composition for culturing or growing corneal endothelial cells, comprising at least one agent consisting of laminins and fragments thereof which express in corneal endothelial cells. Specifically, the present invention can comprise laminin 511 (alpha5 beta1 gamma1) and laminin 512 (alpha5 beta2 gamma 1). The present invention further provides a culture container for corneal endothelial cells, which is coated with the composition of the present invention. Furthermore, the present invention provides a method for culturing corneal endothelial cells comprising the step of using the composition or the container of the present invention to culture the corneal endothelial cells.Type: GrantFiled: November 26, 2014Date of Patent: April 11, 2023Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, ActualEyes Inc., CorneaGen, Inc.Inventors: Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita, Friedrich E. Kruse, Ursula Schloetzer-Schrehardt
-
Patent number: 11607425Abstract: The present invention provides a kidney production method including a step of tissue-specifically removing a metanephric mesenchyme of a metanephros of a non-human animal; a step of transplanting a human kidney precursor cell into the metanephros; and a step of advancing development of the metanephros, which is a step in which the transplanted human kidney precursor cell is differentiated and matured to form a part of the kidney.Type: GrantFiled: June 8, 2017Date of Patent: March 21, 2023Assignees: BIOS Co., LtdInventors: Takashi Yokoo, Shuichiro Yamanaka
-
Patent number: 11602588Abstract: A method of treating soft tissue conditions. A harvesting device is provided. The harvesting device is operably connected to a tissue processing device using tubing. An aperture is formed in a bone. The bone has an interior. The harvesting device is inserted through the aperture in the bone and into the interior of the bone. The harvesting device is manipulated to dissociate connective tissue progenitor cells in the interior of the bone. Tissue is aspirated from the interior of the bone. The connective tissue progenitor cells are separated from the aspirated tissue. The separated connective tissue progenitor cells are injected in a region of a body that is experiencing a soft tissue condition to treat the soft tissue condition.Type: GrantFiled: June 4, 2018Date of Patent: March 14, 2023Assignee: ForCyte Medical, LLCInventors: Robert Assell, Andy Freeman
-
Patent number: 11603398Abstract: Provided herein are methods and compositions for the amelioration of inflammatory disorders comprising the intestinal expression of programmed death ligand 1.Type: GrantFiled: November 9, 2017Date of Patent: March 14, 2023Inventors: Shauna Marie Dauphinee, Connor Daniel Alexander McCarthy, Jeremy Dupaul-Chicoine, Eric Hsu, Ghania Chikh, Anthony Cheung
-
Patent number: 11603539Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: May 13, 2013Date of Patent: March 14, 2023Assignee: CELLECTISInventors: Roman Galetto, Agnès Gouble, Stéphanie Grosse, Cécile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Patent number: 11596512Abstract: This disclosure describes decellularized, biologically-engineered tubular grafts and methods of making and using such decellularized, biologically-engineered tubular grafts.Type: GrantFiled: December 31, 2020Date of Patent: March 7, 2023Assignee: Regents of the University of MinnesotaInventors: Robert Tranquillo, Zeeshan Syedain, Lee Meier
-
Patent number: 11591572Abstract: The invention relates to differentiation methods for progenitor cells, e.g. mammalian epithelial stem cells, differentiation media for use in said methods, organoids and cells obtainable by said methods and uses, including therapeutic uses, thereof.Type: GrantFiled: March 1, 2017Date of Patent: February 28, 2023Assignee: Koninklijke Nederlandse Akademie Van WetenschappenInventors: Johannes Carolus Clevers, Helmuth Gehart
-
Patent number: 11590172Abstract: Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: March 8, 2019Date of Patent: February 28, 2023Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Samson Tom, Alla Danilkovitch, Dana YOo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Patent number: 11589575Abstract: The present invention relates to a solution for the preservation of cells from placental blood, from bone marrow and from peripheral blood.Type: GrantFiled: September 9, 2016Date of Patent: February 28, 2023Assignees: ETABLISSEMENT FRANCAIS DU SANG, UNIVERSITÉ DE BORDEAUX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Zoran Ivanovic, Jean Chevaleyre, Laura Rodriguez, Esther Attebi
-
Patent number: 11581059Abstract: Embodiments of the invention describe to methods of diagnosing, classifying, and/or identifying a patient's risk of developing graft versus host disease, including severe or lethal graft versus host disease, after receiving hematopoietic cellular transplantation, a transfusion or a transplantation, but before the onset of clinical symptoms.Type: GrantFiled: October 20, 2017Date of Patent: February 14, 2023Assignee: Icahn School of Medicine at Mount SinaiInventors: James Ferrara, John E. Levine, Umut Özbek
-
Patent number: 11578306Abstract: Provided are methods for propagating mesenchymal stem cells (MSC), and particularly adipose derived stem cells, including incubating isolated cells obtained from a tissue or organ including MSC in a growth medium including an apoptosis inducing agent, under specified conditions. Further provided is an isolated cell population and kits for performing the methods.Type: GrantFiled: September 22, 2016Date of Patent: February 14, 2023Assignee: CELLECT BIOTHERAPEUTICS LTD.Inventors: Tal Almog, Shai Yarkoni
-
Patent number: 11564943Abstract: The invention refers to a decomposed platelet concentrate containing ?50% intact platelets and optionally ?200 pg/ml RANTES and specifically to its use in the prevention or treatment of hair loss and/or for promoting hair growth. The invention further refers to a composition comprising the decomposed platelet concentrate and body fat cells and the use of said composition for reconstructive and aesthetic and curative surgery and pain relief treatment.Type: GrantFiled: January 21, 2016Date of Patent: January 31, 2023Inventor: Edvin Turkof
-
Patent number: 11560546Abstract: The present invention relates generally to the field of cell biology of stem cells, more specifically the directed differentiation of pluripotent or multipotent stem cells, including human embryonic stem cells (hESC), somatic stem cells, and induced human pluripotent stem cells (hiPSC) using novel culture conditions. Specifically, methods are provided for obtaining neural tissue, floor plate cells, and placode including induction of neural plate development in hESCs for obtaining midbrain dopamine (DA) neurons, motor neurons, and sensory neurons. Further, neural plate tissue obtained using methods of the present inventions are contemplated for use in co-cultures with other tissues as inducers for shifting differentiation pathways, i.e. patterning.Type: GrantFiled: February 20, 2019Date of Patent: January 24, 2023Assignee: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Stuart Chambers, Lorenz Studer
-
Patent number: 11559605Abstract: The present invention provides a kidney production method including a step of tissue-specifically removing a metanephric mesenchyme of a metanephros of a non-human animal; a step of transplanting, into the metanephros, a kidney precursor cell derived from a non-human animal which is allogeneic or xenogeneic to the non-human animal; and a step of advancing development of the metanephros, which is a step in which the transplanted kidney precursor cell is differentiated and matured to form a part of the kidney.Type: GrantFiled: June 8, 2017Date of Patent: January 24, 2023Assignees: BIOS CO., LTDInventors: Takashi Yokoo, Shuichiro Yamanaka
-
Patent number: 11555180Abstract: Micro-Organosphers, including Patient-Derived Micro-Organospheres (PMOS s), apparatuses and methods of making them, and apparatuses and methods of using them. Also described herein are methods and systems for screening a patient using these Patient-Derived Micro-Organospheres, including personalized therapies.Type: GrantFiled: April 1, 2020Date of Patent: January 17, 2023Assignees: Xilis, Inc., Duke UniversityInventors: Xiling Shen, David Hsu, Jeffrey Motschman, Daniel Delubac, Zhaohui Wang
-
Patent number: 11547780Abstract: An inducer is directed to the induction of in situ regeneration in regenerative medicine. The inducer including an extracellular matrix and/or a bone morphogenetic protein, can induce the regeneration of bone and soft tissues surrounding the bone such as muscle, blood vessel and skin at the residual tissues where trauma occurs. The amount of regenerated tissue is associated with the dose of the implanted inducer.Type: GrantFiled: March 29, 2019Date of Patent: January 10, 2023Inventor: Yingqin Liu
-
Patent number: 11547731Abstract: Methods of treating inflammation, pain or both inflammation and pain in a subject are provided. The method includes the step of administering a human birth tissue material composition on or within an affected site of a body. The methods are particularly suitable for treatment of inflammation, pain or both inflammation and pain arising from a viral infection.Type: GrantFiled: July 3, 2018Date of Patent: January 10, 2023Assignee: BRAHM HOLDINGS, LLCInventor: Timothy R. Brahm
-
Patent number: 11542563Abstract: A method for discriminating between live and dead microbes in a sample, by discriminating between transcriptionally-active and inert microbial nucleic acid sequences in the sample. In particular, the method is based on the comparison of levels of nucleotide substitution in a sample cultured in presence of an RNA-labelling agent. Also, a diagnosis method of microbial infections in a subject; and methods of assessing the risk of contamination of a sample, implementing the method for discriminating between live and dead microbes in a sample.Type: GrantFiled: October 20, 2020Date of Patent: January 3, 2023Assignee: PATHOQUESTInventors: Marc Eloit, Pascale Beurdeley, Stéphane Cruveiller
-
Patent number: 11542328Abstract: The present invention relates in part to the discovery of genes that are deregulated in cancer stem cells (e.g., melanoma stem cells). In some aspects, methods for treating individuals having melanoma are provided; the methods involve modulating (e.g., inducing, inhibiting, etc.) the activity of the cancer stem cell associated genes. In other aspects, cell surface genes that are upregulated in melanoma stem cells are targeted for the selective isolation, detection, and killing of cancer stem cells in melanoma. Other aspects of the invention relate to reagents, arrays, compositions, and kits that are useful for diagnosing and treating melanoma.Type: GrantFiled: June 10, 2019Date of Patent: January 3, 2023Assignees: The Brigham and Women's Hospital, Inc., Children's Medical Center CorporationInventors: Markus H. Frank, Natasha Y. Frank
-
Patent number: 11534401Abstract: A room temperature injectable thermo-responsive hydrogel comprises a P407 poloxamer base hydrogel, chitosan, 2-Hydroxypropyl ?-cyclodextrin and genipin. The chitosan and genipin form an interpenetrating scaffold within the hydrogel in which the chitosan is crosslinked with genipin. Chemotherapeutic drugs can be added to the hydrogel singly or in combination in effective amounts without any loss of thermo-responsiveness in the hydrogel. Therapeutic use of the thermo-responsive hydrogel in the intratumoural treatment of solid cancer is also described.Type: GrantFiled: November 7, 2018Date of Patent: December 27, 2022Assignee: THE ROYAL COLLEGE OF SURGEONS IN IRELANDInventors: Helena Kelly, Garry Duffy, Seona Rossi, Conn Hastings
-
Patent number: 11530384Abstract: The invention relates to the use of matrix cells for obtaining a micro hair follicle and to the use thereof for evaluating the effect of cosmetic, pharmaceutical or dermatological products and also for the prophylactic or therapeutic treatment of a state of reduced pilosity.Type: GrantFiled: September 28, 2016Date of Patent: December 20, 2022Assignee: L'OREALInventors: Khalid Bakkar, Christine Collin-Djangone
-
Patent number: 11529300Abstract: Provided are formulations that interact with the skin microbiome of a human patient such that when applied topically in therapeutically effective amounts at prescribed intervals, the formulations cause an increase in skin firmness, density, smoothness, elasticity and thickness resulting in a skin appearance that reflects overall skin health. In exemplary embodiments formulations include, without limitation, the following active components acting in concert with each other: a prebiotic component, a peptide component, a matrix metalloproteinases (MMPs) inhibitor component; and an antioxidant component; all present in a carrier base. The exemplary embodiments may be in the form of a cream, a lotion, a serum, or a hydrogel that facilitates delivery of these active components into the skin.Type: GrantFiled: July 3, 2019Date of Patent: December 20, 2022Assignee: JAMRM, LLCInventors: Tatiana Kelly, Alisar Salah Zahr, John Koch, Nirmal Shah, Thu Quynh Nguyen
-
Patent number: 11512283Abstract: Well-defined, xeno-free culture media which comprise a TGF-beta isoform or the chimera formed between IL6 and the soluble IL6 receptor (IL6RIL6), which are capable of maintaining stem cells, and particularly, human embryonic stem cells, in an undifferentiated state are provided. Also provided are cell cultures comprising the culture media and the stem cells and methods of expanding and deriving embryonic stem cells in such well-defined, xeno-free culture media. In addition, the present invention provides methods of differentiating ESCs or EBs formed therefrom for the generation of lineage specific cells.Type: GrantFiled: June 27, 2019Date of Patent: November 29, 2022Assignee: Technion Research & Development Foundation LimitedInventors: Michal Amit, Joseph Itskovitz-Eldor